Taiwan Liposome Company Total Liabilities

Taiwan Liposome Company (TLC) currently reports a total liabilities of $780M as of June 2021. That compares with $780M in the prior-year period — down 0.1% year over year. Use the charts on this page to explore Taiwan Liposome Company's total liabilities history and peer comparisons.

Taiwan Liposome Company's total liabilities decreased from $780M to $780M — a 0.1% year-over-year decrease (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taiwan Liposome Company reported $780M in total liabilities as of June 2021. That compares with $780M in the prior-year period — down 0.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $780M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Taiwan Liposome Company, and consider following TLC for alerts when major investors trade the stock.

Taiwan Liposome Company is classified in the Healthcare sector. On total liabilities, it currently shows $780M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TLC with unrelated industries.